日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway

更正：对TRAIL诱导化合物的鉴定突显了小分子ONC201/TIC10作为一种独特的抗癌药物，它能够激活TRAIL通路。

期刊:Molecular Cancer
影响因子:33.9
doi:10.1186/s12943-024-02158-w
Allen, Joshua E; Krigsfeld, Gabriel; Patel, Luv; Mayes, Patrick A; Dicker, David T; Wu, Gen Sheng; El-Deiry, Wafik S
信号转导
肿瘤
肿瘤免疫
TRAIL
发表日期：2024
文献求助 收藏

First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis

一线伊布替尼治疗慢性淋巴细胞白血病患者的总生存率与年龄匹配的一般人群相似：一项汇总的事后分析

期刊:Hemasphere
影响因子:14.6
doi:10.1002/hem3.74
Ghia, Paolo; Owen, Carolyn; Allan, John N; Barrientos, Jacqueline C; Barr, Paul M; Shi, Chunxue; Szoke, Anita; Abbazio, Christopher; Krigsfeld, Gabriel S; Burger, Jan A
白血病
细胞生物学
发表日期：2024
文献求助 收藏

Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

在开始使用维奈克拉治疗前，使用伊布替尼进行有效的肿瘤减瘤：来自 CAPTIVATE 微小残留病灶和固定疗程队列的研究结果

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-0504
Barr, Paul M; Tedeschi, Alessandra; Wierda, William G; Allan, John N; Ghia, Paolo; Vallisa, Daniele; Jacobs, Ryan; O'Brien, Susan; Grigg, Andrew P; Walker, Patricia; Zhou, Cathy; Ninomoto, Joi; Krigsfeld, Gabriel; Tam, Constantine S
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

一线伊布替尼治疗TP53异常慢性淋巴细胞白血病患者的长期疗效：四项临床试验的汇总分析

期刊:British Journal of Haematology
影响因子:3.8
doi:10.1111/bjh.17984
Allan, John N; Shanafelt, Tait; Wiestner, Adrian; Moreno, Carol; O'Brien, Susan M; Li, Jianling; Krigsfeld, Gabriel; Dean, James P; Ahn, Inhye E
白血病
细胞生物学
P53
发表日期：2022
文献求助 收藏

Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types

对多种肿瘤类型中 PD-L1 IHC 28-8 和 22C3 pharmDx 检测的实际应用、周转时间和分析一致性进行分析

期刊:Journal of Clinical Pathology
影响因子:2
doi:10.1136/jclinpath-2020-206466
Krigsfeld, Gabriel S; Prince, Emily A; Pratt, James; Chizhevsky, Vladislav; William Ragheb, Josette; Novotny, James Jr; Huron, David
PD-L1
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏

Distinct vascular genomic response of proton and gamma radiation-A pilot investigation

质子和伽马射线对血管基因组的不同反应——一项初步研究

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0207503
Ricciotti, Emanuela; Sarantopoulou, Dimitra; Grant, Gregory R; Sanzari, Jenine K; Krigsfeld, Gabriel S; Kiliti, Amber J; Kennedy, Ann R; Grosser, Tilo
发表日期：2019
文献求助 收藏

CancerInSilico: An R/Bioconductor package for combining mathematical and statistical modeling to simulate time course bulk and single cell gene expression data in cancer

CancerInSilico：一个 R/Bioconductor 软件包，用于结合数学和统计建模来模拟癌症中随时间变化的细胞整体和单细胞基因表达数据。

期刊:PLoS Computational Biology
影响因子:3.6
doi:10.1371/journal.pcbi.1006935
Sherman, Thomas D; Kagohara, Luciane T; Cao, Raymon; Cheng, Raymond; Satriano, Matthew; Considine, Michael; Krigsfeld, Gabriel; Ranaweera, Ruchira; Tang, Yong; Jablonski, Sandra A; Stein-O'Brien, Genevieve; Gaykalova, Daria A; Weiner, Louis M; Chung, Christine H; Fertig, Elana J
细胞生物学
肿瘤
肿瘤免疫
单细胞
发表日期：2018
文献求助 收藏

Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations

Taselisib (GDC-0032) 是一种有效的 β 阻断型 PI3K 小分子抑制剂，可增强含有激活 PIK3CA 变异的头颈部鳞状细胞癌的放射敏感性

期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-15-2245
Zachary S Zumsteg, Natasha Morse, Gabriel Krigsfeld, Gaorav Gupta, Daniel S Higginson, Nancy Y Lee, Luc Morris, Ian Ganly, Stephan L Shiao, Simon N Powell, Christine H Chung, Maurizio Scaltriti, José Baselga
免疫
细胞生物学
头颈癌
肿瘤细胞
PI3K/Akt
发表日期：2016
文献求助 收藏

CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network

CoGAPS矩阵分解算法可识别EGFR网络治疗性抑制反馈中AP-2α靶基因的转录变化。

期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.12075
Fertig, Elana J; Ozawa, Hiroyuki; Thakar, Manjusha; Howard, Jason D; Kagohara, Luciane T; Krigsfeld, Gabriel; Ranaweera, Ruchira S; Hughes, Robert M; Perez, Jimena; Jones, Siân; Favorov, Alexander V; Carey, Jacob; Stein-O'Brien, Genevieve; Gaykalova, Daria A; Ochs, Michael F; Chung, Christine H
EGFR
EGF
发表日期：2016
文献求助 收藏

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway

TRAIL诱导化合物的鉴定凸显了小分子ONC201/TIC10作为一种独特的抗癌药物，它能够激活TRAIL通路。

期刊:Molecular Cancer
影响因子:33.9
doi:10.1186/s12943-015-0346-9
Allen, Joshua E; Krigsfeld, Gabriel; Patel, Luv; Mayes, Patrick A; Dicker, David T; Wu, Gen Sheng; El-Deiry, Wafik S
信号转导
肿瘤
肿瘤免疫
TRAIL
发表日期：2015
文献求助 收藏